 REDWOOD CITY, Calif., Jan. 07, 2021 GLOBE NEWSWIRE -- Graybug Vision, Inc. Nasdaq: GRAY, a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the last patient visit in its GB-102 Phase 2b ALTISSIMO core trial the 12-month treatment phase in wet age-related macular degeneration wet AMD. ALTISSIMO 12-month topline data are expected to be announced in the second quarter of 2021, with full results to be presented at a medical conference later in the year. 